Cellevolve Announces Global Partnership with QIMR Berghofer Medical Research Institute to Advance Novel Off-the Shelf T-cell Therapy in the First Randomized Cell Therapy Trial for Progressive Multifocal Leukoencephalopathy (PML)
Retrieved on:
Wednesday, December 1, 2021
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Patient, BK, Demyelinating disease, HLA, PML, CE, Human polyomavirus 2, NORD, Company, Immunodeficiency, Center, VST, Partnership, MD, JC, Match, MBA, QIMR Berghofer Medical Research Institute, IND, Progressive multifocal leukoencephalopathy, George Washington University School of Medicine & Health Sciences, Central nervous system, Doctor of Philosophy, ISCB Senior Scientist Award, BK virus, Therapy, Professor, Infrastructure as code, Washington University School of Medicine, Research, NASDAQ, Derrell, Social media, HIV disease progression rates, QIMR, FDA, Science, Regenerative medicine, Bio, Disease, Immunotherapy, Clinical Neuropharmacology, Pharmaceutical industry, Vaccine
Cellevolve Bio (the Company or Cellevolve), a development and commercialization company focused on cell therapies, today announced a broad-based collaboration with Australia-based QIMR Berghofer Medical Research Institute and its cell therapy manufacturing facility Q-Gen Cell Therapeutics.
Key Points:
- Cellevolve Bio (the Company or Cellevolve), a development and commercialization company focused on cell therapies, today announced a broad-based collaboration with Australia-based QIMR Berghofer Medical Research Institute and its cell therapy manufacturing facility Q-Gen Cell Therapeutics.
- The initial therapeutic focus is on progressive multifocal leukoencephalopathy (PML), a demyelinating disease of the central nervous system caused by JC polyomavirus (JCPyV) occurring in immunocompromised patients.
- We are honored to partner with leading VST researcher Professor Khanna and his team at QIMR Berghofer to advance a novel, bioengineered, JCV-specific off-the-shelf T-cell therapy to the clinic in this first randomized cell therapy clinical trial.
- Cellevolve has received initial FDA feedback for its clinical development plan for the JCPyV VST (CE-VST01-JC) and IND submission is planned for the first half of 2022.